HomeCompareRROYF vs MRK

RROYF vs MRK: Dividend Comparison 2026

RROYF yields 7.67% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RROYF wins by $196.0K in total portfolio value
10 years
RROYF
RROYF
● Live price
7.67%
Share price
$0.28
Annual div
$0.02
5Y div CAGR
32.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$252.8K
Annual income
$100,957.05
Full RROYF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — RROYF vs MRK

📍 RROYF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRROYFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RROYF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RROYF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RROYF
Annual income on $10K today (after 15% tax)
$651.75/yr
After 10yr DRIP, annual income (after tax)
$85,813.49/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, RROYF beats the other by $77,485.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RROYF + MRK for your $10,000?

RROYF: 50%MRK: 50%
100% MRK50/50100% RROYF
Portfolio after 10yr
$154.8K
Annual income
$55,377.59/yr
Blended yield
35.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

RROYF
No analyst data
Altman Z
-0.5
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RROYF buys
0
MRK buys
0
No recent congressional trades found for RROYF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRROYFMRK
Forward yield7.67%2.76%
Annual dividend / share$0.02$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR32.8%32.7%
Portfolio after 10y$252.8K$56.8K
Annual income after 10y$100,957.05$9,798.13
Total dividends collected$212.9K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RROYF vs MRK ($10,000, DRIP)

YearRROYF PortfolioRROYF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,718$1,018.26$11,206$366.19+$512.00RROYF
2$14,019$1,480.94$12,650$502.35+$1.4KRROYF
3$17,200$2,198.97$14,407$694.19+$2.8KRROYF
4$21,752$3,348.31$16,585$967.82+$5.2KRROYF
5$28,530$5,255.53$19,342$1,363.89+$9.2KRROYF
6$39,083$8,555.32$22,913$1,947.19+$16.2KRROYF
7$56,364$14,545.52$27,662$2,823.89+$28.7KRROYF
8$86,345$26,035.18$34,159$4,173.35+$52.2KRROYF
9$141,889$49,500.39$43,337$6,308.80+$98.6KRROYF
10$252,778$100,957.05$56,776$9,798.13+$196.0KRROYF

RROYF vs MRK: Complete Analysis 2026

RROYFStock

RE Royalties Ltd. engages in the acquisition of revenue-based royalties from renewable energy generation facilities and other clean energy technologies by providing a non-dilutive royalty financing solution to privately held and publicly traded renewable energy generation and development companies, and clean energy technology companies. As of April 25, 2022, it owned a portfolio 104 royalties on solar, wind, hydro, battery storage, and renewable natural gas projects in Canada, Europe, and the United States. The company is headquartered in Vancouver, Canada.

Full RROYF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this RROYF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RROYF vs SCHDRROYF vs JEPIRROYF vs ORROYF vs KORROYF vs MAINRROYF vs JNJRROYF vs ABBVRROYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.